Skip to main content
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Cited by
    This book has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Thorens, Gabriel Gex-Fabry, Marianne Zullino, Daniele F and Eytan, Ariel 2008. Attitudes toward psychopharmacology among hospitalized patients from diverse ethno-cultural backgrounds. BMC Psychiatry, Vol. 8, Issue. 1,


Book description

No one reacts or responds to a drug in exactly the same way, just as no two persons are exactly alike. Individual and ethnic differences in drug response have been consistently found in clinical practice. This book covers all the important factors that explain how and why drug treatments used in psychiatry affect individuals and ethnic groups differently. It will increase understanding of how biological differences interact with social, cultural and environmental factors to bring about overall effects of medications, particularly in individuals from various ethnicities. This book uniquely brings these varied aspects together to consider a holistic approach to drug therapy across diverse biological make-up and cultures. This information has direct practical use in the clinical setting.


'The book is, at the same time, both conceptually fascinating and clinically relevant. There are clinical pearls scattered throughout and a central theme of patient-centred care pervades the book. Ideally suited for clinicians who prescribe psychiatric medications, the book also is interesting and has relevance to those who do not prescribe … the book does a wonderful job summarising the research in this area and guiding clinicians with some basic principles of patient care … Ethno-psychopharmacology is a breath of fresh air.'

Source: PsycCritiques

'… a good addition to the library of anyone interested in the broad topic of cultural psychiatry. It reminds us that the importance of culture and ethnicity is not only to be seen in the context of symptom expression, or even in that of prevalence of disorders, but in the equally important context of how and why we often respond or fail to respond to psychotropic drugs.'

Source: British Journal of Psychiatry

'… a good grounding in understanding variations in psychotropic drug response between cultures, and would be especially useful to clinicians and those implementing psychiatric care schemes.'

Source: Journal of Mental Health

    • Aa
    • Aa
Refine List
Actions for selected content:
Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Send to Kindle
  • Send to Dropbox
  • Send to Google Drive
  • Send content to

    To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to .

    To send content to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

    Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

    Find out more about the Kindle Personal Document Service.

    Please be advised that item(s) you selected are not available.
    You are about to send:

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

Agbayani-Siewert, P., Takeuchi D. & Pangan, R. (1999). Mental illness in a multicultural context. In C. Aneshensel and J. Phelann , eds., Handbook of the Sociology of Mental Health.New York: Kluwer Academic/Plenum Publishers, pp. 19–36.

M. Alegria , D. Takeuchi , G. Canino et al. (2004). Considering context, place and culture: The National Latino and Asian American Study. Int. J. Methods Psychiatr. Res., 13(4), 208–20.

J. W. Berry (1997). Immigration, acculturation, and adaptation. Applied Psychology: An International Review, 46(1), 5–34.

Berry, J. W. (2006). Acculturative stress. In P. T. P. Wong & L. C. J. Wong , eds., Handbook of Multicultural Perspectives on Stress and Coping. Dallas, TX: Spring Publications, pp. 287–98.

J. W. Berry , J. S. Phinney , D. L. Sam & P. Vedder (2006). Immigrant youth: acculturation, identity, and adaptation. Applied Psychology: An International Review, 55(3), 303–32.

A. Blackledge (2003). Imagining a monocultural community: racialization of cultural practice in educational discourse. J. Language, Identity, and Education, 2(4), 331–47.

J. T. Cacioppo & G. G. Berntson (1992). Social psychological contributions to the decade of the brain: doctrine of multilevel analysis. Am. Psychol., 47(8), 1019–28.

J. E. Cameron & R. N. Lalonde (1994). Self, ethnicity, and social group memberships in two generations of Italian Canadians. Pers. Soc. Psychol. Bull., 20(5), 514–20.

C. Cheng , F. Lee & V. Benet-Martínez (2006). Assimilation and contrast effects in cultural frame switching: bicultural identity integration and valence of cultural cues. J. Cross Cult. Psychol., 37(6), 742–60.

F. M. Cheung (1989). The indigenization of neurasthenia in Hong Kong. Cult. Med. Psychiatry, 13, 227–41.

F. M. Cheung & W. Bernard (1982). Situational variations of help-seeking behavior among Chinese patients. Compr. Psychiatry, 23(3), 252–62.

H. Fábrega (1995). Cultural challenges to the psychiatric enterprise. Compr. Psychiatry, 36(5), 377–83.

P. J. Guarnaccia , R. Angel & Worobey , J. L. (1989). The factor structure of the CES-D in the Hispanic Health and Nutrition Examination Survey: the influences of ethnicity, gender, and language. Soc. Sci. Med., 29(1), 85–94.

J. S. Jackson , H. W. Neighbors , M. Torres et al. (2007). Use of mental health services and subjective satisfaction with treatment among Black Caribbean immigrants: results from the National Survey of American Life. Am. J. Public Health, 97(1), 60–7.

H. H. L. Kitano (1962). Changing achievement patterns of the Japanese in the United States. J. Soc. Psychol., 58(2), 257–64.

A. M. Kleinman (1977). Depression, somatization and the new cross-cultural psychiatry. Soc. Sci. Med., 11(1), 3–10.

T. Lin (1982). Culture and psychiatry: a Chinese perspective. Aust. N. Z. J. Psychiatry, 16(4), 235–45.

R. G. Malgady , L. H. Rogler & D. E. Cortes (1996). Cultural expression of psychiatric symptoms: idioms of anger among Puerto Ricans. Psychol. Assess., 8, 265–8.

A. J. Marsella (1988). Cross-cultural research on severe mental disorders: issues and findings. Acta Psychiatr. Scand., 78(344 Suppl), 7–22.

A. J. Marsella , D. Kinzie & P. Gordon (1973). Ethnic variations in the expression of depression. J. Cross Cult. Psychol., 4(4), 435–58.

J. E. Mezzich (1979). Patterns and issues in multiaxial psychiatric diagnosis. Psychol. Med., 9(1) 125–7.

J. E. Mezzich , H. Fabrega & A. Kleinman (1992). Cultural validity and DSM-IV (editorial). J. Nerv. Ment. Dis., 180, 4.

Z. Ming-Yuan (1989). The diagnosis and phenomenology of neurasthenia: a Shanghai study. Cult. Med. Psychiatry, 13(2), 147–61.

A. J. Rubel (1964). The study of Latino folk illnesses. Med. Anthropol., 15(2), 209–13.

W. Searle & C. Ward (1990). The prediction of psychological and sociocultural adjustment during cross-cultural transitions. Intl. J. Intercultural Relations, 14(4), 449–64.

D. W. Sue & B. A. Kirk (1975). Asian-Americans: use of counseling and psychiatric services on a college campus. J. Counseling Psychology, 22(1), 84–6.

J. Szapocznik & W. M. Kurtines (1993). Family psychology and cultural diversity: opportunities for theory, research, and application. Am. Psychol., 48(4), 400–7.

E. F. Torrey (1995). Prevalence of psychosis among the Hutterites: a reanalysis of the 1950–53 study. Schizophr. Res., 16(2), 167–70.

H. C. Triandis (1993). Collectivism and individualism as cultural syndromes. Cross-Cultural Research: The Journal of Comparative Social Science, 27(3–4), 155–80.

W-S. Tseng (1975). The nature of somatic complaints among psychiatric patients: the Chinese case. Compr. Psychiatry, 16(3), 237–45.

C. Ward & A. Kennedy (1999). The measurement of sociocultural adaptation. Intl. J. Intercultural Relations, 23(4), 659–77.

R. G. Wight , A. L. Botticello & C. S. Aneshensel (2006). Socioeconomic context, social support, and adolescent mental health: a multilevel investigation. J. Youth and Adolescence, 35(1), 115–26.

D. R. Williams , Y. Yu & J. S. Jackson (1997). Racial differences in physical and mental health: socio-economic status, stress and discrimination. Journal of Health Psychology, 2(3), 335–51.

J. Yamamoto , Q. C. James & N. Palley (1968). Cultural problems in psychiatric therapy. Arch. Gen. Psychiatry, 19(1), 45–9.

K. E. Anderson & Kappas A. (1991). Dietary regulation of cytochrome P450. Annu. Rev. Nutr., 11, 141–67.

S. Beratis , Katrivanou, A. et al. (2001). Factors affecting smoking in schizophrenia. Compr. Psychiatry, 42(5), 393–402.

R. A. Branch , Salih, S. Y. et al. (1978). Racial differences in drug metabolizing ability: a study with antipyrine in the Sudan. Clin. Pharmacol. Ther., 24(3), 283–6.

J. Y. Choi , Lee, K. M. et al. (2003). CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics, 13(6), 349–55.

M. L. Dahl , Yue, Q. Y. et al. (1995). Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics, 5(3), 159–64.

H. S. Fraser , Mucklow, J. C. et al. (1979). Environmental factors affecting antipyrine metabolism in London factory and office workers. Br. J. Clin. Pharmacol., 7(3), 237–43.

U. Fuhr , Klittich, K. et al. (1993). Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol., 35(4), 431–6.

J. Gelernter , Kranzler, H. et al. (1997). Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum. Genet., 101(2), 243–6.

B. D. Greenberg , McMahon, F. J. et al. (1998). Serotonin transporter candidate gene studies in affective disorders and personality: promises and potential pitfalls. Mol. Psychiatry, 3(3), 186–9.

A. R. Hariri & Weinberger, D. R. (2003). Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav., 2(6), 341–9.

H. Kim , Lim, S. W. et al. (2006). Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA, 296(13), 1609–18.

J. B. Leathart , London, S. J. , et al. (1998). CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 8(6), 529–41.

K. M. Lin & Cheung, F. (1999). Mental health issues for Asian Americans. Psychiatr. Serv., 50(6), 774–80.

K. M. Lin , Poland, R. E. et al. (1988). Haloperidol and prolactin concentrations in Asians and Caucasians. J. Clin. Psychopharmacol., 8(3), 195–201.

Y. H. Liou , Lin, C. T. et al. (2006). The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J. Hum. Genet., 51(10), 857–63.

J. B. Lohr & Flynn, K. (1992). Smoking and schizophrenia. Schizophr. Res., 8(2), 93–102.

C. M. Masimirembwa & Hasler, J. A. (1997). Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain. Res. Bull., 44(5), 561–71.

L. G. Miller (1989). Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin. Pharmacokinet., 17(2), 90–108.

J. Oesterheld & Kallepalli, B. R. (1997). Grapefruit juice and clomipramine: shifting metabolitic ratios. J. Clin. Psychopharmacol., 17(1), 62–3.

C. A. Roby , Anderson, G. D. et al. (2000). St John's Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 67(5), 451–7.

J. J. Schildkraut , Kopin, I. J. et al. (1995). Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968. Pharmacopsychiatry, 28 (1): 24–37.

S. L. Wang , Huang, J. D. et al. (1993). Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther., 53(4), 410–18.

H. G. Xie , Stein, C. M. et al. (1999). Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 9(5), 539–49.

K. Yoshida , Ito, K. et al. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26(2), 383–6.

Y. W. Yu , Tsai, S. J. et al. (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry, 7(10), 1115–19.

R. Zanardi , Serretti, A. et al. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry, 50(5), 323–30.

S. Zevin & Benowitz, N. L. (1999). Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet., 36(6), 425–38.

J. Ananth et al. (2005). Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opin. Drug Saf., 4, 1111–24.

K. E. Anderson et al. (1991). Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology, 13, 941–6.

A. G. Awad et al. (1995). Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol., 10(3), 123–32.

S. E. Ball et al. (1999). Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther., 66, 288–94.

C. Beedham , J. J. Miceli & R. S. Obach (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol., 23, 229–32.

L. Bertilsson et al. (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol., 38, 471–3.

E. B. Binder & F. Holsboer (2006). Pharmacogenomics and antidepressant drugs. Ann. Med., 38, 82–94.

S. Botts , R. Littrell & J. Leon (2004). Variables associated with high olanzapine dosing in a state hospital. J. Clin. Psychiatry, 65, 1138–43.

S. Caccia (2000). Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet., 38, 393–414.

J. A. Carrillo et al. (2003). Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol., 23, 119–27.

L. Carulli et al. (2005). Review article: diabetes, genetics and ethnicity. Aliment. Pharmacol. Ther., 22(2), 16–19.

H. Y. Chan et al. (2007). Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J. Clin. Psychiatry, 68, 29–36.

P. Dalen et al. (1998). 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther., 63, 444–52.

A. K. Daly et al. (1996). Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193–201.

J. Leon (2003). Glucuronidation enzymes, genes and psychiatry. Int. J. Neuropsychopharmacol., 6, 57–72.

J. Leon , S. C. Armstrong & K. L. Cozza (2005b). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–73.

J. Leon et al. (2007). Weight gain during a double-blind multidosage clozapine study. J. Clin. Psychopharmacol., 27, 22–7.

M. Eichelbaum , M. Ingelman-Sundberg & W. E. Evans (2006). Pharmacogenomics and individualized drug therapy. Annu. Rev. Med., 57, 119–37.

R. A. Emsley et al. (2002). Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J. Clin. Psychiatry, 63, 9–14.

W. E. Evans & J. A. Johnson (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet., 2, 9–39.

W. E. Evans & M. V. Relling (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487–91.

U. Fuhr (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf., 18, 251–72.

T. Fukuda et al. (2000). The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur. J. Clin. Pharmacol., 56, 175–80.

M. Gaviria , A. A. Gil & J. I. Javaid (1986). Nortriptyline kinetics in Hispanic and Anglo subjects. J. Clin. Psychopharmacol., 6, 227–31.

J. Gelernter et al. (1999). Population studies of polymorphisms of the serotonin transporter protein gene. Am. J. Med. Genet., 88, 61–6.

R. Grohmann et al. (1989). Adverse effects of clozapine. Psychopharmacology, 99, S101–4.

F. P. Guengerich (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39, 1–17.

R. Hwang et al. (2005). Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology, 181, 179–87.

K. Inoue et al. (1997). Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103–13.

K. Ito et al. (2002). A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res, 111, 235–9.

C. W. Jackson , J. S. Markowitz & T. D. Brewerton (1995). Delirium associated with clozapine and benzodiazepine combinations. Ann. Clin. Psychiatry, 7, 139–41.

M. W. Jann et al. (1989). Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res., 30, 45–52.

M. W. Jann et al. (1992). Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog. Neuropsychopharmacol. Biol. Psychiatry, 16, 193–202.

B. Janssen et al. (2004). Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr. Bull., 30, 1023–33.

L. B. Jorde & S. P. Wooding (2004). Genetic variation, classification and ‘race’. Nat. Genet., 36, S28–33.

J. K. Kaholokula et al. (2006). Ethnic-by-gender differences in cigarette smoking among Asian and Pacific Islanders. Nicotine Tob. Res., 8, 275–86.

D. L. Kelly et al. (2006). Clozapine utilization and outcomes by race in a public mental health system: 1994–2000. J. Clin. Psychiatry, 67, 1404–11.

J. Kirchheiner et al. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand., 104, 173–92.

A. Kishimoto & L. Hollister (1984). Nortriptyline kinetics in Japanese and Americans. J. Clin. Psychopharmacol., 4, 171–2.

D. R. Krishna & U. Klotz (1994). Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet., 26, 144–60.

L. A. Kryzhanovskaya et al. (2006). A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J. Clin. Psychiatry, 67, 933–45.

M. Kubo et al. (2005). Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic Aripriprazole. Drug Metab. Pharmacokinet., 20, 55–64.

T. J. R. Lambert & I. H. Minas (1998). Transcultural psychopharmacology and pharmacotherapy. Australasian Psychiatry, 6, 61–4.

H. Y. Lane et al. (2001). A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. J. Clin. Psychiatry, 62, 994–5.

C. Lee et al. (2006). Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust. N. Z. J. Psychiatry, 40, 437–45.

M. S. Lee (2005). The pharmacogenetics of antidepressant treatments for depressive disorders. Drug Dev. Res., 65, 170–8.

K. P. Lesch et al. (1993). Isolation of a cDNA encoding the human brain serotonin transporter. J. Neural Transm. Gen. Sect., 91, 67–72.

J. H. Lin & A. Y. Lu (2001). Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol., 41, 535–67.

K. M. Lin et al. (1988a). Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology, 96, 365–9.

K. M. Lin , M. W. Smith & V. Ortiz (2001). Culture and psychopharmacology. Psychiatr. Clin. North Am., 24, 523–38.

K. Linnet (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol., 17, 233–8.

C. Y. Liu et al. (2003). Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int. Clin. Psychopharmacol., 18, 49–51.

M. L. Lu et al. (2000). Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J. Clin. Psychiatry, 61, 594–9.

M. L. Lu et al. (2004). Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J. Clin. Psychiatry, 65, 766–71.

N. Luo et al. (2004). Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore. Hum. Psychopharmacol., 19, 259–64.

U. A. Meyer (2000). Pharmacogenetics and adverse drug reactions. Lancet, 356, 1667–71.

U. A. Meyer et al. (1996). Antidepressants and drug-metabolizing enzymes – expert group report. Acta Psychiatr. Scand., 93, 71–9.

J. J. Miceli et al. (2000). The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br. J. Clin. Pharmacol., 49(1), 65S–70S.

K. K. Midha et al. (1988a). Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology, 96, 206–11.

K. K. Midha et al. (1988b). A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology, 95, 333–8.

J. O. Miners et al. (2000). Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics, 10, 267–70.

A. Mori et al. (2005). UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos., 33, 672–5.

M. Murray (2006). Role of CYP pharmacogenetics and drug–drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J. Pharm. Pharmacol., 58, 871–85.

D. R. Nelson (1999). Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys., 369, 1–10.

C. H. Ng et al. (2004). The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust. N. Z. J. Psychiatry, 38, 483–9.

C. H. Ng et al. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int. Clin. Psychopharmacol., 20, 163–8.

O. V. Olesen & K. Linnet (2001). Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J. Clin. Pharmacol., 41, 823–32.

B. G. Pollock et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology, 23, 587–90.

S. G. Potkin et al. (1984). Haloperidol concentrations elevated in Chinese patients. Psychiatry Res., 12, 167–72.

K. Raaska , V. Raitasuo , J. Laitila & P. J. Neuvonen (2004). Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Pharmacol. Toxicol., 94, 13–18.

S. Rendic & F. J. Di Carlo (1997). Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29, 413–580.

A. E. Rettie et al. (1994). Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39–42.

H. K. Roh et al. (1996). Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6, 441–7.

M. V. Rudorfer , E. A. Lane , W. H. Chang , M. D. Zhang & W. Z. Potter (1984). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol., 17, 433–40.

F. Sata et al. (2000). CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67, 48–56.

R. S. Schwartz (2001). Racial profiling in medical research. N. Engl. J. Med., 344, 1392–3.

A. Serretti , R. Lilli & E. Smeraldi (2002). Pharmacogenetics in affective disorders. Eur. J. Pharmacol., 438, 117–28.

K. Shimoda et al. (2002). The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J. Clin. Psychopharmacol., 22, 371–8.

K. Sim et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol., 58, 178–83.

M. Sinha et al. (2006). Self-reported race and genetic admixture. N. Engl. J. Med., 354, 421–2.

E. Smeraldi et al. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry, 3, 508–11.

L. K. Sussman , L. N. Robins & F. Earls (1987). Treatment-seeking for depression by black and white Americans. Soc. Sci. Med., 24, 187–96.

L. C. Swartzman & J. Burkell (1998). Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. Clin. Pharmacol. Ther., 64, 1–7.

M. T. Tayeb et al. (2000). CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics, 10, 753–6.

L. Todesco et al. (2003). Determination of -3858G–>A and -164C–>A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G–>A mutation between Caucasians and Asians. Eur. J. Clin. Pharmacol., 59, 343–6.

S. K. Verma et al. (2005). Plasma risperidone levels and clinical response in patients with first-episode psychosis. J. Clin. Psychopharmacol., 25(6), 609–11.

E. S. Vesell (1989). Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther., 41, 535–52.

C. Wandel et al. (2000). CYP3A activity in African American and European American men: popu- lation differences and functional effect of the CYP3A4舗1B5′-promoter region polymorphism. Clin. Pharmacol. Ther., 68, 82–91.

L. Wang et al. (2007). Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci. Lett., 414, 1–4.

U. Weiss et al. (2005). Effects of age and sex on olanzapine plasma concentrations. J. Clin. Psychopharmacol., 25, 570–4.

W. N. Wu & L. A. McKown (2000). Recent advances in biotransformation of CNS and cardiovascular agents. Curr. Drug Metab., 1, 255–70.

H.-G. Xie et al. (2001). Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol., 41, 815–50.

Q. Xing et al. (2006b). Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7, 987–93.

F. Yokoi et al. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and (11C)raclopride. Neuropsychopharmacology, 27, 248–59.

K. Yoshida et al. (2002). Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 1279–83.

Q. Y. Yue et al. (1998). Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther., 64, 384–90.

J. Zhang-Wong et al. (1998). An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res., 81, 333–9.

Z. L. Zhou et al. (2006). Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol. Sin., 27, 381–6.

S. G. Amara & M. J. Kuhar (1993). Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci., 16, 73–93.

B. Arias R. Catalan , C. Gasto , B. Gutierrez & L. Fananas (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol., 23, 563–7.

M. J. Arranz , Collier, D., Sodhi, M. et al. (1995). Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet, 346, 281–2.

M. J. Arranz , Collier, D. A., Munro, J. et al. (1996). Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci. Lett. 217, 177–8.

M. J. Arranz , Munro, J., Owen, M. J. et al. (1998). Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry, 3, 61–6.

V. S. Basile , V. Ozdemir , M. Masellis et al. (2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry, 5, 410–17.

V. S. Basile , M. Masellis , S. G. Potkin & J. L. Kennedy (2002). Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet., 11, 2517–30.

A. V. Benjafield, , C. L. Jeyasingam , D. R. Nyholt , L. R. Griffiths & B. J. Morris (1998). Gprotein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension, 32, 1094–7.

L. Bertilsson (1995). Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet., 29, 192–209.

L. Bertilsson , Y. Q. Lou , Y. L. Du et al. (1992). Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther., 51, 338–97.

B. Bondy & Zill , P. (2004). Pharmacogenetics and psychopharmacology. Curr. Opin. Pharmacol. 4(1), 72–8.

B. Bondy , T. C. Baghai , P. Zill et al. (2002). Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol. Psychiatry, 7, 1120–6.

H. Bonisch & M. Bruss (1994). The noradrenaline transporter of the neuronal plasma membrane. Ann. N.Y. Acad. Sci., 733, 193–202.

S. Boularand , M. C. Darmon , Y. Ganem , J. M. Launay & J. Mallet (1990). Complete coding sequence of human tryptophan hydroxylase. Nucleic Acids Res. 18(14), 4257.

K. Chen , W. Yang , J. Grimsby & J. C. Shih (1992). The human 5HT2A receptor is encoded by a multiple intron exon gene. Brain Res. Mol. Brain Res., 14, 20–6.

M. J. Choi , R. H. Kang , B. J. Ham , H. Y. Jeong & M. S. Lee (2005). Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology, 52, 155–62.

S. P. Craig , S. Boularand , M. C. Darmon , J. Mallet & I. W. Craig (1991). Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenet. Cell Genet., 56, 157–9.

C. Cusin , A. Serretti , R. Zanardi et al. (2002). Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol., 5, 27–35.

M. DeBellis , T. Geracioti & M. Altemus (1993). Cerebrospinal fluid monoamine metabolites in fluoxetine treated patients with major depression and in healthy volunteers. Biol. Psychiatry, 33, 636–41.

Y. Dong , H. Zhu , G. A. Sagnella et al. (1999). Association between the C825T polymorphism of the G protein beta3- subunit gene and hypertension in blacks. Hypertension, 34, 1193–6.

L. K. Durham , S. M. Webb , P. M. Milos , C. M. Clary & A. B. Seymour (2004). The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology, 174, 525–9.

J. Erdmann , D. Shimron-Abarbanell , M. Rietschel et al. (1996). Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum. Genet., 97, 614–19.

C. E. Ford , N. P. Skiba , H. Bae et al. (1998). Molecular basis for interactions of G protein betagamma subunits with effectors. Science, 280, 1271–4.

J. A. Goldstein , T. Ishizaki , K. Chiba et al. (1997). Frequencies of defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7, 59–64.

F. J. Gonzalez & J. R. Idle (1994). Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet., 26, 59–70.

P. Grof , M. Alda , E. Grof , P. Zvolsky & M. Walsh (1994). Lithium response and genetics of affective disorders. J. Affect. Disord., 32, 85–95.

R. J. Guttendorf & P. J. Wedlund (1992). Genetic aspects of drug disposition and therapeutics. J. Clin. Pharmacology, 32, 107–17.

B. J. Ham , M. S. Lee , H. J. Lee et al. (2005). No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressants response in a Korean population. Psychiatr. Genet., 15, 299–301.

B. A. Hamelin , J. Turgeon , F. Vallee et al. (1996). The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther., 60, 512–21.

H. E. Hamm (1998). The many faces of G protein signaling. J. Biol. Chem., 273, 669–72.

R. A. Hegele , C. Anderson , T. K. Young & P. W. Connelly (1999).G-protein beta3 subunit gene splice variant and body fat distribution in Nunavut Inuit. Genome Res., 9, 972–7.

A. Heils , A. Teufel , S. Petri et al. (1996). Allelic variation of human serotonin transporter gene expression. J. Neurochem., 66, 2621–4.

C. Hengstenberg , H. Schunkert , B. Mayer et al. (2001). Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc. Res.,49: 820–7.

H. G. Hwu , Hong, C. W., Lee, Y. L. et al. (1998). Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol. Psychiatry, 44, 483–7.

T. Inaba , D. W. Nebert , B. Burchell et al. (1995). Pharmacokinetics in clinical pharmacology and toxicology. Cana. J. Physiol. Pharmacol., 73, 331–8.

R. Kaiser , Konneker, M., Henneken, M. et al. (2000). Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol. Psychiatry, 5, 418–24.

T. Kapitany , K. Meszaros , E. Lenzinger et al. (1998). Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophr. Schizophr. Res., 32, 101–6.

C. H. Kim , H. S. Kim , J. F. Cubells , & K. S. Kim (1999). A previously undescribed intron and extensive 5′upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J. Biol. Chem.,274, 6507–18.

D. K. Kim , S. W. Lim , S. Lee et al. (2000). Serotonin transporter gene polymorphism and antidepressants response. Neuroreport, 11, 215–19.

R. Kohen M. A. Metcalf N. Khan et al. (1996). Cloning, characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem., 66, 47–56.

H. Kunugi , T. Kato , R. Fukuda et al. (2002). Association study of C825T polymorphism of the G-protein beta3 subunit gene with schizophrenia and mood disorders. J. Neural Transm. 109, 213–18.

L. C. W. Lam , M. M. Garcia-Barcelo , G. S. Ungvari et al. (2001). Cytochrome CYP2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry, 34, 238–41.

H. Y. Lane , Y. C. Chang , C. C. Chiu et al. (2002). Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry, 159, 1593–5.

M. S. Lee , H. Y. Lee , H. J. Lee & S. H. Ryu (2004). Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressants treatment. Psychiatr. Genet., 14, 111–15.

S. H. Lee , K. J. Lee , H. J. Lee et al. (2005). Association between the 5-HT6 receptor C267T polymorphism and response to antidepressants treatment in major depressive disorder. Psychiatry Clin. Neurosci., 59, 140–5.

K. P. Lesch , U. Balling , J. Gross et al. (1994).Organization of the human serotonin transporter gene. J. Neural Transm. Gen. Sect., 95, 157–62.

K. P. Lesch , D. Bengel , A. Heils et al. (1996). Association of anxiety related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274, 1527–31.

C. H. Lin , Tsai, S. J., Yu, Y. W. et al. (1999). No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 10, 57–60.

C. N. Lin , S. J. Tsai & C. J. Hong (2001a). Association analysis of a functional G protein beta3 subunit Gene polymorphism (C825T) in mood disorders. Neuropsychobiology, 44, 118–21.

Y. C. Lou (1990). Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab. Rev., 22, 451–75.

J. Maj , M. Bijak , M. Dziedzicka-Wasylewska et al. (1996).The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology, 127, 73–82.

A. Malhotra , Goldman, D., Ozaki, N. et al. (1996b). Clozapine response and the 5-HT2C Cys23Ser polymorphism. Neuroreport, 7, 2100–2.

A. K. Malhotra , D. Goldman , R. W. Buchanan et al. (1998). The dopamine D-3 receptor (DRD3) Ser-9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol. Psychiatry, 3, 72–5.

M. Masellis , V. S. Basile , V. Ozdemir et al. (2000). Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry, 47, 252–66.

J. Mendlewicz , P. Verbanck , P. Linkowski & J. Wilmotte (1978).Lithium accumulation in erythrocytes of manic-depressive patients: an in vivo twin study. Br. J. Psychiatry, 133, 436–44.

J. H. Meyer , S. Kapur , B. Eisfeld & G. M. Brown (2001). The effect of paroxetine on 5-HT(2A) receptors in depression: an [18F]setoperone PET imaging study. Am. J. Psychiatry, 158, 78–86.

U. A. Meyer (1994b). Pharmacogenetics: the slow, therapid, and the ultrarapid. Proc. Nat. Acad. Sci. USA, 91, 1983–4.

C. Minov , T. C. Baghai , C. Schule et al. (2001).Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci. Lett., 303, 119–22.

D. A. Nielsen , G. L. Jenkins , K. M. Stefanisko , K. K. Jefferson & D. Goldman (1997). Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res. Mol. Brain Res., 45, 145–8.

V. L. Nimgaonkar , Zhang, X. R., Brar, J. S. et al. (1996). 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr. Genet., 6, 23–7.

M. M. Nöthen , Rietschel, M., Erd mann, J. et al. (1995). Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet, 346, 908–9.

M. J. Owens (1997). Molecular and cellular mechanisms of antidepressants drugs. Depress. Anxiety, 4, 153–9.

C. J. Phiel & P. S. Klein (2001). Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol., 41, 789–813.

D. Pickar & K. Rubinow (2001) Pharmacogenomics of psychiatric disorders. Trends Pharmacol. Sci. 22, 75–83.

N. Poolsup , A. Li Wan Po & T. L. Knight (2000). Pharmacogenetics and psychopharmacology. J. Clin. Pharm. Ther., 25, 197–200.

S. Ramamoorthy , A. L. Bauman , K. R. Moore et al. (1993). Antidepressants- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. USA, 90, 2542–6.

P. A. Rao , Packer D., Gejman, P. V. et al. (1994). Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry, 51, 912–17.

J. L. Rausch , M. E. Johnson , Y. J. Fei et al. (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol. Psychiatry, 51, 723–32.

G. P. Reynolds , Z. Zhang & X. Zhang (2003). Polymorphism of the promoter region of the serotonin 5HT(2C) receptor gene and clozapine induced weight gain. Am. J. Psychiatry, 160, 677–9.

Rietschel ., Naber, D., Fimmers, R. et al. (1997). Efficacy and side effects of clozapine not associated with variation in the 5-HT2C receptor. NeuroReport, 8, 1999–2003.

D. Rosskopf , K. Koch , C. Habich et al. (2003). Interaction of Gbeta3s, a splice variant of the G-protein Gbeta3, with Ggamma- and Galpha-proteins. Cell Signal, 15, 479–88.

A. Roy , D. Pickar , J. Dejong , F. Karoum & M. Linnoila (1998). Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch. Gen. Psychiatry, 45, 849–57.

K. Sato , K. Yoshida , H. Takahashi et al. (2002). Association between –1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology, 46, 136–40.

A. C. Scates & P. M. Doraiswamy (2000). Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother., 34, 1302–12.

J. Scharfetter , H. R. Chaudhry , K. Hornik et al. (1999). Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur. Neuropsychopharmacol., 10, 17–20.

P. Seeman & H. H. M. Vantol (1994). Dopamine receptor pharmacology. Trends Pharmacol. Sci., 15, 264–70.

A. Serretti , R. Lilli , C. Lorenzi , L. Franchini & E. Smeraldi (1998). Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int. J. Neuropsychopharmacol., 1, 125–9.

A. Serretti , R. Lilli , C. Lorenzi et al. (1999). Dopamine receptor D2 and D4 genes, GABA(A) alpha- 1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res., 87, 7–19.

A. Serretti , C. Lorenzi , R. Lilli & E. Smeraldi (2000). Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res., 34, 89–98.

A. Serretti , R. Zanardi , C. Cusin et al. (2001a). Tryptophan hydroxylase gene associated with paroxetine antidepressants activity. Eur. Neuropsychopharmacol., 11, 375–80.

A. Serretti , R. Zanardi , D. Rossini et al. (2001b). Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressants activity. Mol. Psychiatry, 6, 586–92.

A. Serretti , C. Lorenzi , C. Cusin et al. (2003). SSRIs antidepressants activity is influenced by Gbeta3 variants. Eur. Neuropsychopharmacol., 13, 117–22.

A. Serretti , P. N. Malitas , L. Mandelli et al. (2004). Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J., 4(4), 267–73.

S. Shaikh , Collier, D. A., Sham, P. et al. (1995). Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am. J. Med. Genet., 60, 541–5.

S. Shaikh , Collier, D. A., Sham, P. C. et al. (1996). Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum. Genet., 97, 714–19.

A. Shaldubina , G. Agam & R. H. Belmaker (2001). The mechanism of lithium action: state of the art, ten years later. Prog. Neuropsychopharmacol. Biol. Psychiatry, 25, 855–66.

W. Siffert (2003). G-protein beta3 subunit 825T allele and hypertension. Curr. Hypertens. Rep., 5, 47–53.

W. Siffert , D. Rosskopf , G. Siffert et al. (1998). Association of a human G protein beta3 subunit variant with hypertension. Nat. Genet., 18, 45–8.

A. J. Sleight , F. G. Boess , M. Bos & A. Bourson (1998). The putative 5-ht6 receptor: localization and function. Ann. N.Y. Acad. Sci., 861, 91–6.

E. Smeraldi , F. Benedetti & R. Zanardi (2002). Serotonin transporter promoter genotype and illness recurrence in mood disorders. Eur. Neuropsychopharmacol. 12, 73–5.

M. S. Sodhi , Arranz, M. J., Curtis, D. et al. (1995). Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport, 7, 169–72.

Spurlock, G. , A. Helis , P. Holmas et al. (1998). A family based association study of T 102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol. Psychiatry, 3, 42–9.

P. Szot , E. A. Ashliegh , Kohen, R. et al. (1993). Norepinephrine transporter mRNA is elevated in the locus coeruleus following short- and long-term desipramine treatment. Brain Res., 618, 308–12.

G. Turecki , P. Grof , E. Grof et al. (2001). Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry, 6, 570–8.

R. C. Veith , N. Lewis , O. A. Linares et al. (1994). Sympathetic nervous system activity in major depression. Arch. Gen. Psychiatry, 51, 411–22.

S. Virchow , N. Ansorge , D. Rosskopf , H. Rubben & W. Siffert (1999). The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8. Naunyn- Schmiedeberg's Arch. Pharmacol., 360, 27–32.

I. R. Vogt , D. Shimron-Abarbanell , H. Neidt et al. (2000). Investigation of the human serotonin 6 [5HT6] receptor gene in bipolar affective disorder and schizophrenia. Am. J. Med. Genet., 96, 217–21.

J. H. Wang , Z. Q. Liu , Wang . et al. (2001). Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther., 70, 42–7.

R. P. Ward , M. W. Hamblin , J. E. Lachowicz et al. (1995). Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience, 64, 1105–11.

W. H. Wu , S. J. Huo , C. Y. Cheng , C. J. Hong & S. J. Tsai (2001). Association study of the 5-HT (6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology, 44, 172–5.

M. Yates , A. Leake , J. M. Candy et al. (1990). 5HT2 receptor changes in major depression. Biol. Psychiatry, 27, 489–96.

L. N. Yatham , P. F. Liddle & J. Dennie (1999). Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch. Gen. Psychiatry, 56, 705–11.

K. Yoshida , H. Takahashi , H. Higuchi et al. (2004). Prediction of antidepressants response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry, 161(9), 1575–80.

M. Yoshioka , M. Matsumoto , H. Togashi & K. Mori (1998). Central distribution and function of 5-HT6 receptor subtype in the rat brain. Ann. N.Y. Acad. Sci., 861, 244.

Y. W. Yu , Tsai, S. J., Lin, C. H. et al. (1999). Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport, 10, 1231–3.

R. Zanardi , F. Benedetti , D. Di Bella , M. Catalano & E. Smeraldi (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol., 20, 105–7.

P. Zill , T. C. Baghai , P. Zwanzger et al. (2000). Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressants treatment. Neuroreport, 11, 1893–7.

P. Zill , R. Engel , T. C. Baghai et al. (2002). Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacol., 26, 489–93.

Y. Fu , C. H. Fan , H. H. Deng et al. (2006b). Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin, 27(3), 328–32.

J. C. Almeida & E. W. Grimsley (1996). Coma from the health food store: interaction between kava and alprazolam. Ann. Intern. Med., 125, 940–1.

M. Alonso , E. Val & M. H. Rapaport (1997). An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. J. Clin. Psychiatry, 58, 31.

American Diabetes Association, American Psychiatrics Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry, 65, 267–72.

G. Beaubrun & G. E. Gray (2000). A review of herbal medicines for psychiatric disorders. Psychiatr. Serv., 51, 1130–4.

J. V. Campo , J. McNabb , J. M. Perel et al. (2002). Kava-induced fulminant hepatic failure. J. Am. Acad. Child Adoles. Psychiatr., 41, 631–2.

K. M. Conner & J. R. Davidson (2002). A placebo-controlled study of kava kava in generalized anxiety disorder. Int. Clin. Psychopharmacol., 17, 185–8.

L. A. Copeland , J. E. Zeber , M. Valenstein & F. C. Blow (2003). Racial disparity in the use of atypical antipsychotic medications among veterans. Am. J. Psychiatry, 160, 1817–22.

P. Casner (2005). The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J. Clin. Pharmacol., 45, 1230–5.

M. B. Currier , G. Molina & M. Kato (2004). Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics, 45, 210–16.

G. L. Daumit , R. M. Crum , E. Guallar , N. R. Powe et al. (2003). Outpatient prescriptions for atypical antispsychotics for African Americans, Hispanics, and whites in the United States. Arch. Gen. Psychiatry, 60, 121–8.

R. A. Dominguez , R. L. Bravo-Valverde , B. R. Kaplowitz & J. M. Cott (2000). Valerian as a hypnotic for Hispanic patients. Cultur. Divers. Ethnic Minor. Psychol., 6, 84–92.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 285, 2486–97.

B. A. Fallon , A. I. Qureshi , F. Schneier , A. Sanchez-Lacy et al. (2003). An open trial of fluvoxamine for hypochondriasis. Psychosomatics, 44, 298–303.

S. J. Ferrando , J. G. Rabkin , G. M. Moore & R. Rabkin (1999). Antidepressant treatment of depression in HIV-seropositive women. J. Clin. Psychiatry, 60, 741–6.

E. S. Ford , W. H. Giles & W. H. Dietz (2002). Prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA, 287, 356–9.

A. Fugh-Berman (2000). Herb–drug interactions. Lancet, 355, 134–8.

K. Fukuda , T. Ohra & Y. Yamazoe (1997). Grapefruit component interacting with rat and human P450 CYP3A: possible involvement on non-flavonoid components in drug interaction. Biol. Pharm. Bull., 20, 560–4.

G. V. Gupchup , U. L. Abhyankar , M. M. Worley , D. W. Raisch et al. (2006). Relationships between Hispanic ethnicity and attitudes and beliefs toward herbal medicine in older adults. Res. Social Adm. Pharm., 2, 266–79.

D. C. Henderson (2002). Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 16, 77–89.

A. A. Izzo & E. Ernst (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs, 61, 2163–75.

L. Johnson , H. Strich , A. Taylor , B. Timmermann et al. (2006). Use of herbal remedies by diabetic Hispanic women in the southwestern united states. Phytother. Res., 20, 250–5.

M. M. Kato , M. B. Currier , C. M. Gomez et al. (2004). Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim. Care Companion J. Clin. Psychiatry, 6, 74–7.

E. Kuno & A. B. Rothbard (2002). Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am. J. Psychiatry, 159, 567–72.

Y. Lecrubier , G. Clerc , R. Didi & M. Kieser (2002). Efficacy of St. John's Wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry, 159, 1361–6.

R. Lewis-Fernandez , C. Blanco , C. H. Mallinkcrodt , M. M. Wohlreich et al. (2006). Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority Caucasian patients. J. Clin. Psychiatry, 67, 1379–90.

A. LLerena , P. Dorado , O' F. Kirwan et al. (2004). Lower frequency of CYP2C9∗2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J., 4, 403–6.

H. R. Luo , A Gaedigk , V. Aloumanis & Y. Y. Wan (2005). Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur. J. Clin. Pharmacol., 61, 797–802.

H. R. Luo , R. Poland , K. M. Lin & Y. Y. Wan (2006). Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans a cross ethnic comparative study. Clin. Pharmacol. Ther., 80, 33–40.

R. D. Marshall , R. Lewis-Fernandez , C. Blanco , H. B. Simpson et al. (2007). A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress. Anxiety, 24, 77–84.

R. Mendoza , Y. J. Wan , R. E. Poland et al. (2001). CYP 2D6 in a Mexican American population. Clin. Pharmacol. Ther., 70, 552–60.

J. M. Meyer , H. A. Nasrallah , J. P. McEvoy , D. C. Goff et al. (2005). The clinical antipsychotic trials of intervention effectiveness trial: clinical comparison of subgroups with and without metabolic syndrome. Schizophr. Res., 80, 9–18.

J. Miranda , J. Y. Chung , B. L. Green , J. Krupnick et al. (2003). Treating depression in predominantly low-income young minority women. JAMA, 290, 57–65.

D. Mischoulon (2002). The herbal anxiolytics kava and valerian for anxiety and insomnia. Psychiatric Annals, 32, 55–60.

B. Ng , A. Camacho , A. Simmons & S. C. Matthews (2006). Ethnicity and use of alternative products in psychiatric patients. Psychosomatics, 47, 408–13.

J. L. Opolka , K. L. Rascati , C. M. Brown , J. C. Barner et al. (2003). Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. J. Clin. Psychiatry, 64, 635–9.

N. C. Patel , M. L. Crismon , A. Shafer , A. Leon , M. Lopez et al. (2006). Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. Soc. Psychiatry. Psychiatr. Epidemiol., 41, 341–6.

A. P. Popli , P. E. Konicki , G. J. Jurjus , M. A. Fuller et al. (1997). Clozapine and associated diabetes mellitus. J. Clin. Psychiatry, 58, 108–11.

P. P. Roy-Byrne , P. Philip , C. Pitts & J. Christi (2005). Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. J. Clin. Psychiatry, 66, 1228–33.

J. A. Sanchez-Lacay , R. Lewis-Fernandez , D. Goetz , C. Blanco et al. (2001). Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues. Depress. Anxiety, 13, 118–24.

M. S. Santos , F. Ferreira , C. Faro et al. (1994). The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H] GABA release in synaptosomes. Planta Med., 60, 475–6.

F. R. Schneier , C. Blanco , R. Campeas , R. Lewis-Fernandez et al. (2003). Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety, 17, 191–6.

E. Schrader (2000). Equivalence of St John's Wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild–moderate depression. Int. Clin. Psychopharmacol., 15, 61–8.

V. Schulz , R. Hansel & V. E. Tyler (2001). Rational Phytotherapy: A Physicians' Guide to Herbal Medicine, 4th ed. Berlin: Springer.

M. J. Sernyak , D. L. Leslie , R. D. Alarcon , M. F. Losonczy et al. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry, 159, 561–6.

D. J. Stein , M. B. Stein , C. D. Pitts , R. Kumar et al. (2002). Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of three placebo-controlled paroxetine trials. J. Clin. Psychiatry, 63, 152–5.

L. L. Watkins , K. M. Conner & J. R. Davidson (2001). Effect of kava extract on vagal cardiac control in generalized anxiety disorder; preliminary findings. J. Psychopharmacol., 15, 283–6.

M. Valenstein , L. A. Copeland , R. Owen , F. C. Blow et al. (2001). Adherence assessments and the use of depot antipsychotic medications in patients with schizophrenia. J. Clin. Psychiatry, 62, 545–54.

M. Versiani , A. Ontiveros , G. Mazzotti , J. Ospina et al. (1999). Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int. Clin. Psychopharmacol., 14, 321–7.

L. D. Bradford (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3, 229–43.

P. Carson , S. Ziesche , G. Johnson et al. (1999). Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J. Card. Fail., 5, 178–87.

G. Corbie-Smith , S. B. Thomas , M. V. Williams et al. (1999). Attitudes and beliefs of African-Americans toward participation in medical research. J. Gen. Int. Med., 14, 537–46.

J. Leon , M. T. Susce , R. M. Pan , M. Fairchild et al. (2005). The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry, 66, 15–27.

W. S. Fenton & M. R. Chavez (2006). Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am. J. Psychiatry, 163, 1697–704.

D. V. Jeste , M. P. Caligiuri & J. S. Paulsen (1995). Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch. Gen. Psychiatry, 52, 756–65.

A. M. Kilbourne & H. A. Pincus (2006). Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatry Serv., 57, 123–6.

F. J. McMahon , S. Buervenich , D. Charney et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet., 78, 804–14.

C. A. Melfi , T. W. Croghan , M. P. Hanna et al. (2000). Racial variation in antidepressant treatment in a Medicaid population. J. Clin. Psychiatry, 61, 16–21.

H. Morgenstern & W. M Glazer (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry, 50, 723–33.

E. H. Pi & G. M. Simpson (2005). Cross-cultural psychopharmacology: a current clinical perspective. Psychiatry Serv., 56, 31–3.

P. Sankar & J. Kahn (2005). BiDil: Race medicine or race marketing? Health Affairs, web exclusive (

I. Schillevoort , A. Boer , J. Weide et al. (2002). Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics, 12, 235–40.

V. L. Shavers , C. F. Lynch & L. F. Burmeister (2002). Racial differences in factors that influence the willingness to participate in medical research studies. Ann. Epidemiol., 12, 248–56.

T. L. Strickland , K. M. Lin , P. Fu , D. Anderson et al. (1995). Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol. Psychiatry, 37, 325–30.

T. S. Stroup , J. A. Lieberman , J. P. McEvoy et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry, 163, 611–22.

A. L. Taylor , Ziesche, S., Yancy, C. et al. (2004). Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. N. Engl. J. Med., 351, 2049–57.

M. H. Trivedi , A. J. Rush , S. R. Wisniewski et al. (2006). STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am. J. Psychiatry, 163, 28–40.

M. Valenstein , J. F. McCarthy , K. L. Austin et al. (2006). What happened to lithium? Antidepressant augmentation in clinical settings. Am. J. Psychiatry, 163, 1219–25.

D. Wendler , R. Kington , J. Madans et al. (2006). Are racial and ethnic minorities less willing to participate in health research? PLoS Med., 3, e19.

I. Ajzen (2001). Nature and operation of attitudes. Annu. Rev. Psychol., 52, 27–58.

R. Angel & P. Thoits (1987). The impact of culture on the cognitive structure of illness. Cult. Med. Psychiatry, 11, 465–94.

A. G. Awad (1993). Subjective response to neuroleptics in schizophrenia. Schizophr. Bull., 19, 609–18.

L. W. Buckalew & K. Coffield . (1982). Drug expectations associated with perceptual characteristics. Percept. Mot. Skills, 55, 915–18.

P. C. Carder , N. Vuckovic & C. A. Green (2003). Negotiating medications: patient perceptions of long-term medication use. J. Clin. Pharm. Ther., 28, 409–17.

A. S. David (1990). Insight and psychosis. Br. J. Psychiatry, 156, 798–808.

J. C. Day , R. P. Bentall , C. Roberts et al. (2005). Attitudes toward antipsychotic medication. Arch. Gen. Psychiatry, 62, 717–24.

W. S. Fenton , C. R. Blyler & R. K. Heinssen (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull., 23, 637–51.

T. P. Hogan , A. G. Awad & R. Eastwood (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med., 13, 177–83.

R. Horne & J. Weinman (1999). Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical disease. J. Psychosom. Res., 47(6), 555–67.

R. Horne , L. Graupner , S. Frost et al. (2004). Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc. Sci. Med., 59, 1307–13.

O. Kampman , K. Lehtinen , V. Lassila et al. (2000). Attitudes towards neuroleptic treatment: reliability and validity of the Attitudes towards Neuroleptic Treatment (ANT) questionnaire. Schizophr. Res., 45, 223–34.

J. D. Kinzie , P. Leung , J. K. Boehnlein & J. Fleck (1987). Antidepressant blood levels in Southeast Asians. Clinical and cultural implications. J. Nerv. Ment. Dis., 175(8), 480–5.

R. P. L. Lee (1980). Perceptions and uses of Chinese medicine among the Chinese in Hong Kong. Cult. Med. Psychiatry, 4, 345–75.

S. Lee (1993). Side effect of chronic lithium therapy in Hong Kong Chinese: an ethnopsychiatric perspective. Cult. Med. Psychiatry, 17, 301–20.

H. Leventhal , M. Diefenbach & E. A. Leventhal (1992). Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cogn. Ther. Res., 16, 143–63.

K.-M. Lin & W. W. Shen (1991). Pharmacotherapy for Southeast Asian psychiatric patients. J. Nerv. Ment. Dis., 179, 346–50.

K.-M. Lin , M. H. Miller , R. E. Poland , I. Nuccio & M. Yamaguchi (1991). Ethnicity and family involvement in the treatment of schizophrenic patients. J. Nerv. Ment. Dis., 179, 631–3.

J. Mantonakis , M. Markidis , V. Kontaxakis & A. Liakos (1985). A scale for detection of negative attitudes towards medication among relatives of schizophrenic patients. Acta Psychiatr. Scand., 71, 186–9.

D. E. Moerman (1979). Anthropology of symbolic healing. Curr. Anthropology, 20, 59–80.

D. E. Morisky , L. W. Green & D. M. Levine (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care, 24, 67–74.

H. B. M. Murphy (1969). Ethnic variations in drug response. Transcultural Psychiatric Research Review, 6, 6–23.

C. Ng (1997). The stigma of mental illness in Asian cultures. Aust. N. Z. J. Psychiatry, 31, 382–90.

P. A. Nutting , K. Post , J. Smith , J. J. Werner & C. Elliot (2000). Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch. Fam. Med., 9, 1959–64.

G. Parker , G. Gladstone & K.-T. Chee (2001). Depression in the planet's largest ethnic group: the Chinese. Am. J. Psychiatry, 158, 857–64.

S. Priebe (1987). Early subjective reactions predicting outcome of hospital treatment in depressive patients. Acta Psychiatr. Scand., 76, 134–8.

C. Seale , R. Chaplin , P. Lelliott & A. Quirk (2006). Sharing decisions in consultations involving anti-psychotic medication: a qualitative study of psychiatrists' experiences. Soc. Sci. Med., 62, 2861–73.

K. Thompson , J. Kulkarni & A. Sergejew (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr. Res., 42, 241–7.

T. Putten & P. R. A. May (1978). Subjective response as a predictor of outcome in pharmacotherapy. Arch. Gen. Psychiatry, 35, 477–80.

L. N. P. Voruganti & A. G. Awad (2002). Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr. Res., 56, 37–46.

S. J. Ziguras , S. Klimidis , T. J. R. Lambert & A. C. Jackson (2001). Determinants of anti-psychotic medication compliance in a multicultural population. Community Ment. Health J., 37(3), 273–83.

M. Y. Chong , C. H. Tan , S. Fujii et al. (2004). Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci., 58(1), 61–7.

T. A. Furukawa , T. Kitamura & K. Takahashi (2000). Treatment received by depressed patients in Japan and its determinants: naturalistic observation from multi-center collaborative follow-up study. J. Affect. Disord., 60(3), 173–9.

W. F. Huang & I. C. Lai (2005). Patterns of sleep – related medications prescribed to elderly outpatients with insomnia in Taiwan. Drugs Aging, 22(11), 957–65.

E. H. Pi , A. L. Wang & G. E. Gray (1993). Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 17(5), 691–702.

M. Srisurapanont , P. Garner , J. Critchley & N. Wongpakaran (2005). Benzodiazepine prescribing behaviour and attitudes: a survey among general practitioners practicing in northern Thailand. BMC Fam. Pract., 6, 27.

S. Yamawaki (1999). The use and development of anxiolytics in Japan. Eur. Neuropsychopharmacol, 9(suppl 6), S413–S419.

H. Chiu , S. Lee , C. M. Leung & Y. K. Wing (1992). Neuroleptic prescription for Chinese schizophrenics in Hong Kong. Aust. N. Z. J. Psychiatry, 26(2), 262–4.

N. H. Covell , C. T. Jackson , A. C. Evans & S. M. Essock (2002). Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr. Bull., 28(1), 17–29.

S. A. Hull , P. Aquino & S. Cotter (2005). Explaining variation in antidepressant prescribing rates in east London: a cross sectional study. Fam. Pract., 22(1), 37–42.

D. S. Jones & R. H. Perlis (2006). Pharmacogenetics, race, and psychiatry: prospects and challenges. Harv. Rev. Psychiatry, 14(2), 92–108.

Y. W. Lam , M. W. Jann , W. H. Chang et al. (1995). Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. J. Clin. Pharmacol., 35(2), 128–36.

J. L. Opolka , K. L. Rascati , C. M. Brown & P. J. Gibson (2004). Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr. Serv., 55(2), 151–6.

R. H. Perlis , C. S. Perlis , Y. Wu et al. (2005). Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am. J. Psychiatry, 162(10), 1957–60.

K. Sim , A. Su , J. Y. Leong et al. (2004a). High dose antipsychotic use in schizophrenia: findings of the REAP (research on East Asia psychotropic prescriptions) study. Pharmacopsychiatry, 37(4), 175–9.

K. Sim , A. Su , G. S. Ungvari et al. (2004b). Depot antipsychotic use in schizophrenia: an East Asian perspective. Human Psychopharmacology, 19, 103–9.

B. Sleath & Y. C. Shih (2003). Sociological influences on antidepressant prescribing. Soc. Sci. Med., 56(6), 1335–44.

Sartorius, N. (2001). Psychiatry in developing countries. In F. Henn , N. Sartorius , H. Helmchen and H. Lauter , eds., Contemporary Psychiatry, Vol. 2. Berlin, Heidelberg, New York: Springer Verlag, pp. 247–59.

N. Sartorius & R. A. Elmsley (2000). Psychiatry and technological advances: implications for the developing countries. Lancet, 356, 2090–2.

S. Snelders , C. Kaplan & T. Peters (2006). On cannabis, chloral hydrate and career cycle of psychotropic drugs in medicine, Bull. Hist. Med., 80(1), 95–114 cited in Jefferson J. W. & Greist J. H. (2006). Rethinking older psychiatric drugs. Primary Psychiatry, December 2006, 37–8.

M. Aaserud , A. T. Dahlgren , J. P. Kösters et al. (2006). Pharmaceutical policies: effects of ref- erence pricing, other pricing, and purchasing policies. Cochrane Database Syst. Rev., 19(2), CD005979.

W. A. Banks (2006). The blood–brain barrier in psychoneuroimmunology. Neurol. Clin., 24(3), 413–19.

M. L. Block & J. S. Hong (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol., 76(2), 77–98.

M. D. Cabana , C. S. Rand , N. R. Powe et al. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement. J.A.M.A., 282(15), 1458–65.

A. Carlsson (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1(3), 179–86.

M.-L. Chen & C.-H. Chen (2005a). Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment. J. Psychiatric Res., 41(1/2), 63–8.

M.-L. Chen & C.-H. Chen (2005b). Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology, 30(2), 268–77.

D. Cook & M. Giacomini (1999). The trials and tribulations of clinical practice guidelines. J.A.M.A., 281(20), 1950–1.

R. Dantzer (2006). Cytokine, sickness behavior, and depression. Neurol. Clin., 24(3), 441–60.

J. Leon (2006). AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev. Mol. Diagn., 6, 277–86.

C. Debouck & P. N. Goodfellow (1999). DNA microarrays in drug discovery and development. Nat. Genet., 21, 48–50.

E. F. Domino (1999). History of modern psychopharmacology: a personal view with an emphasis on antidepressants. Psychosom. Med., 61(5), 591–8.

R. S. Duman & L. M. Monteggia (2006). A neurotrophic model for stress-related mood disorders. Biol. Psychiatry, 59(12), 1116–27.

G. S. Ginsburg , R. P. Konstance , J. S. Allsbrook & K. A. Schulman (2005). Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med., 165(20), 2331–6.

J. Graham , L. Christian & J. Kiecolt-Glaser (2006). Stress, age, and immune function: toward a lifespan approach. J. Behav. Med., 29, 389–400.

M. F. Green & D. L. Braff (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol. Psychiatry 49(4), 374–84.

M. J. Hallworth (2004). The drugs dont work: pharmacogenomics – clinical biochemistry's future? Ann. Clin. Biochem., 41, 260–2.

D. Healy (2002). The Creation of Psychopharmacology.Cambridge, MA: Harvard University Press.

T. Ishikawa , Y. Onishi , H. Hirano et al. (2004). Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol. Pharm. Bull., 27, 939–48.

G. Kempermann & G. Kronenberg (2003). Depressed new neurons? Adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol. Psychiatry, 54(5), 499–503.

K. S. Kendler (2005). Toward a philosophical structure for psychiatry. Am. J. Psychiatry, 162(3), 433–40.

S. U. Kim & J. Vellis (2005). Microglia in health and disease. J. Neurosci. Res., 81(3), 302–13.

J. Kirchheiner , K. Nickchen , M. Bauer et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 9, 442–73.

M. Kremer (2002). Pharmaceuticals and the developing world. J. Econ. Perspect., 16(4), 67–90.

B. D. Lebowitz & M. V. Rudorfer (1998). Treatment research at the millennium: from efficacy to effectiveness. J. Clin. Psychopharmacol., 18(1), 1.

H.-J. Lee , J.-H. Cha , B.-J. Ham et al. (2004). Association between a G-protein bold beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J., 4, 29–33.

J. A. Lieberman , T. S. Stroup , J. P. McEvoy et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353(12), 1209–23.

A. K. Malhotra , G. M. Murphy , Jr. & J. L. Kennedy (2004). Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry, 161(5), 780–96.

H. K. Manji , J. A. Quiroz , J. Sporn et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry, 53(8), 707–42.

C. Martinelli & J.-M. Reichhart (2005). Evolution and integration of innate immune systems from fruit flies to man: lessons and questions. J. Endotoxin Res., 11, 243–8.

L. Matowe & D. R. Katerere (2002). Globalization and pharmacy: a view from the developing world. Ann. Pharmacother., 36(5), 936–8.

J. Moncrieff (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials. J. Nerv. Ment. Dis., 189(5), 288–95.

N. Müller & M. J. Schwarz (2006). Neuroimmune endocrine crosstalk in schizophrenia and mood disorders. Expert Rev. Neurother., 6, 1017–38.

N. W. Paul & H. Fangerau (2006). Why should we bother? Ethical and social issues in individualized medicine. Curr. Drug Targets, 7, 1721–7.

R. H. Perlis , D. A. Ganz , J. Avorn et al. (2005). Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J. Clin. Psychopharmacol., 25(5), 427–34.

M. H. Rapaport , K. K. Delrahim , C. J. Bresee et al. (2005). Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry, 57(12), 1594–6.

A. D. Roses (2001). Pharmacogenetics. Hum. Mol. Genet., 10, 2261–7.

A. J. Rush , M. Fava , S. R. Wisniewski et al. (2004). Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design. Controlled Clinical Trials, 25(1), 119–42.

A. A. Russo-Neustadt & M. J. Chen (2005). Brain-derived neurotrophic factor and antidepressant activity. Curr. Pharm. Des., 11, 1495–510.

L. E. Schechter , R. H. Ring , C. E. Beyer et al. (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx, 2(4), 590–611.

A. Serretti & E. Smeraldi (2004). Neural network analysis in pharmacogenetics of mood disorders. BMC Med. Genet., 5(1), 27.

A. Serretti , C. Cusin , D. Rossini et al. (2004). Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet., 129B(1), 36–40.

A. Serretti , F. Benedetti , R. Zanardi & E. Smeraldi (2005). The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog. Neuro psychopharmacol. Biol. Psychiatry, 29(6), 1074–84.

S. M. Stahl (2006). Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx, 3(1), 3–9.

G. Tucker (2004). Pharmacogenetics – expectations and reality. B.M.J. 329(7456), 4–6.

R. Weinshilboum & L. Wang (2004). Pharmacogenomics: bench to bedside. Nat Rev. Drug Discov., 3(9), 739–48.

K. B. Wells (1999). Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am. J. Psychiatry, 156(1), 5–10.

Y. Ziv , N. Ron , O. Butovsky et al. (2006). Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci., 9(2), 268–75.

L. Lesko & J. Woodcock (2002). Pharmacogenetic-guided drug development: regulatory perspective. Pharmacogenomics J., 2, 20–4.

C. H. Ng , S. Easteal , S. Tan et al. (2006b). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog. Neuropsychopharmacol. Biol. Psychiatry, 30, 953–7.


Full text views

Total number of HTML views: 0
Total number of PDF views: 24 *
Loading metrics...

Book summary page views

Total views: 68 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 28th April 2017. This data will be updated every 24 hours.